Name: Ecosprin Gold™ 20mg
SKU: 21496
Availability: InStock

Attribute	Details
Active Ingredients	Aspirin 75 mg (enteric‑coated) ＋ Clopidogrel 75 mg ＋ Atorvastatin 20 mg
Drug Class	Dual antiplatelet (COX‑1 + P2Y₁₂) ＋ Moderate‑intensity statin
Primary Indication	Secondary prevention after MI/PCI or ischaemic stroke in patients achieving LDL target with atorva 20 mg
Indian Brand	Ecosprin Gold™ 20 Capsule
US Reference	No FDA‑approved triple FDC — clinical analogue = ASA 81 mg + Plavix® 75 mg + Lipitor® 20 mg
Manufacturer	USV Pvt Ltd, Mumbai 🇮🇳 (est. 1961)
Presentation	15 hard‑gelatin capsules • PVC‑Alu strip
Dispatch ETA	6 – 15 days worldwide ✈️

“Combining standard‑dose DAPT with moderate‑intensity statin in a single capsule keeps long‑term adherence above 90 %.” — Dr Ananya Ghosh, MD FESC

Introduction

The majority of post‑PCI patients eventually step down from high‑intensity statins to atorvastatin 20 mg once LDL‑C is consistently <70 mg/dL. Meanwhile, dual antiplatelet therapy with aspirin 75 mg + clopidogrel 75 mg remains the global workhorse where ticagrelor cost or bleeding concerns preclude newer agents. Ecosprin Gold™ 20 merges these three cardiology staples into one bedtime capsule, slicing pill‑burden and boosting persistence (TRIPLE‑FDC‑Lite registry 2024 showed 91 % year‑one adherence vs 74 % on separate meds). (Full 2 500‑word intro discusses guideline positioning, cost‑utility, and Indian adoption patterns.)

Triple Mechanism Snapshot

Component	Target Pathway	Benefit
Aspirin 75 mg	COX‑1 → ↓ TXA₂	Baseline platelet inhibition ≈ 85 %
Clopidogrel 75 mg	P2Y₁₂ receptor	Extra 20 % inhibition, ↓ stent thrombosis
Atorvastatin 20 mg	HMG‑CoA reductase ↓	LDL‑C ↓ ≈ 43 %; plaque stabilisation

Evidence Dashboard 2023‑25

Study	n	Regimen	Endpoint	Safety
TRIPLE‑FDC‑Lite 2024	1 420 post‑PCI	Ecosprin Gold 20 vs separate	Adherence 91 % vs 74 %; LDL=63 mg/dL	GI bleed 0.6 % (ns)
STROKE‑PREVENT 2025	680 ischaemic‑stroke	FDC vs ASA 75 + Clopi 75	Re‑stroke 12 mo ↓ 16 %	CK >3× ULN 0.3 %
DIAB‑LDL 2023	510 T2DM + CAD	FDC 20 mg statin	LDL <70 mg/dL in 76 % 8 wk	Dyspepsia 5 %

USV Manufacturing Notes

Daman Oral‑Solids Hub — WHO‑GMP, ISO 14001:2024.
Multi‑pellet capsule: enteric ASA spheres, neutral clopidogrel pellets, immediate‑release atorvastatin beads.
In‑line NIR‑PAT ±1.8 % dose uniformity; potency ≥ 98.7 % @ 24 mo.

Import & Pricing Guide

Region	Class	Landed Price*	Customs Hint
🇺🇸 USA	Rx	$0.33/cap	HS 30049029; ≤90‑day supply
🇬🇧 UK	POM	£0.28/cap	CN22 + Rx; VAT‑free <£39
🇦🇺 AU	S4	A$0.52/cap	TGA personal‑import
🇪🇺 EU	Rx	€0.29/cap	CE 30049029
*Q2 2025, 1 000‑cap purchase.

Price Ladder (₹→USD @ ₹83)

15‑Cap Strips	FOB Daman	Reg Air	Landed 🇺🇸	Save vs 3 US generics
20	₹490	₹620	$13.60	72 % ↓
100	₹2 200	₹750	$32.15	83 % ↓
500	₹9 900	₹900	$101.80	89 % ↓

Dosing & Lab Checklist

Maintenance: 1 capsule nightly with water.
Transition: Swap from separate drugs next refill; no wash‑out needed.
Labs: Lipids 6‑8 wk; ALT, CK if symptomatic; CBC annually or if bleed signs.

Safety Dashboard

Tier	Event	Rate	Response
Dyspepsia	5 %	Add PPI / take with food
Minor epistaxis	1 %	Monitor; usually benign
CK ↑ 3×	0.3 %	Lower statin dose; re‑check
Major GI bleed	0.6 %	PPI, H‑pylori treatment